Media stories about GlaxoSmithKline PLC (NYSE:GSK) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline PLC earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the pharmaceutical company an impact score of 45.6910587437959 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

A number of research analysts recently issued reports on GSK shares. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, April 25th. TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $46.00.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.32% on Wednesday, reaching $39.53. 3,262,264 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $42.44 and a 200-day moving average price of $41.81. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59. The company has a market cap of $96.61 billion, a PE ratio of 38.23 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.97%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 194.00%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Earning Somewhat Positive Media Coverage, Accern Reports” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with's FREE daily email newsletter.